{"transactions":[{"id":717888,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T20:30:26.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 30, 2026 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."}],"balance_after":32000,"derivative":{"exercise_price":3.66,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001193125-26-294697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000119312526294697/ownership.xml","form_type":"4"}},{"id":919370,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:15:06.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":10.8726,"value":163089.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. This Form 4/A corrects the weighted average price indicated in the Form 4 submitted on January 6, 2026 from $11.8726 to $10.8726."}],"balance_after":469864,"source":{"system":"sec-edgar","filing":"0001193125-26-037606","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000119312526037606/ownership.xml","form_type":"4/A","original_submission_date":"2026-01-06"}},{"id":919369,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-04T21:10:04.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":10.7238,"value":160857.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.48 to $11.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":454864,"source":{"system":"sec-edgar","filing":"0001193125-26-037573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000119312526037573/ownership.xml","form_type":"4"}},{"id":946658,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:30:20.000Z","date":"2026-01-02","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":11.8726,"value":178089.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":469864,"source":{"system":"sec-edgar","filing":"0001193125-26-004572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000119312526004572/ownership.xml","form_type":"4"}},{"id":991267,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-21T21:15:03.000Z","date":"2025-11-19","kind":"sale","planned":false,"acquired":false,"shares":15000,"price":11.033,"value":165495.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.50 to $11.18, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":484864,"source":{"system":"sec-edgar","filing":"0001193125-25-291392","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000119312525291392/ownership.xml","form_type":"4"}},{"id":1099229,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-30T20:15:05.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":36000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 26, 2025 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."}],"balance_after":36000,"derivative":{"exercise_price":7.38,"expiration_date":"2035-06-25","underlying":"Common Stock","underlying_shares":36000},"source":{"system":"sec-edgar","filing":"0000950170-25-091578","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000095017025091578/ownership.xml","form_type":"4"}},{"id":1462943,"issuer":{"id":76646,"kind":"organization","name":"Turnstone Biologics Corp.","symbol":"TSBX"},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-07-02T20:45:14.000Z","date":"2024-06-03","kind":"grant","planned":false,"acquired":true,"shares":12770,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":12770,"derivative":{"exercise_price":2.69,"expiration_date":"2034-06-02","underlying":"Common Stock","underlying_shares":12770},"source":{"system":"sec-edgar","filing":"0001415889-24-018926","document":"form4-07022024_040708.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000141588924018926/form4-07022024_040708.xml","form_type":"4"}},{"id":1475239,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-18T20:20:14.000Z","date":"2024-06-17","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."}],"balance_after":30000,"derivative":{"exercise_price":7,"expiration_date":"2034-06-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-074888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000095017024074888/ownership.xml","form_type":"4"}},{"id":1841984,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-29T20:16:13.000Z","date":"2023-06-27","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."}],"balance_after":30000,"derivative":{"exercise_price":3.16,"expiration_date":"2033-06-26","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-23-030753","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000095017023030753/ownership.xml","form_type":"4"}},{"id":2054714,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim President & CEO"}}],"security":"Common Stock","published_at":"2023-01-13T23:33:36.000Z","date":"2023-01-13","kind":"sale","acquired":false,"shares":6766,"price":15,"value":101490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 7, 2022."}],"balance_after":499864,"source":{"system":"sec-edgar","filing":"0000899243-23-001803","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924323001803/doc4.xml","form_type":"4"}},{"id":2219363,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-29T21:00:44.000Z","date":"2022-06-27","kind":"grant","acquired":true,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service."}],"balance_after":19000,"derivative":{"exercise_price":5.22,"expiration_date":"2032-06-26","underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0000899243-22-024527","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322024527/doc4.xml","form_type":"4"}},{"id":2239105,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-08T23:33:55.000Z","date":"2022-06-07","kind":"exercise","acquired":false,"shares":71435,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the \"2016 Plan\") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement. Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022."}],"balance_after":86523,"derivative":{"exercise_price":7.84,"expiration_date":"2022-06-30","underlying":"Common Stock","underlying_shares":71435},"source":{"system":"sec-edgar","filing":"0000899243-22-021530","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021530/doc4.xml","form_type":"4"}},{"id":2239104,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-08T23:33:55.000Z","date":"2022-06-07","kind":"sale","acquired":false,"shares":71435,"price":8.0898,"value":577894.863,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.35, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-021530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021530/doc4.xml","form_type":"4"}},{"id":2239103,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-08T23:33:55.000Z","date":"2022-06-07","kind":"exercise","acquired":true,"shares":71435,"price":7.84,"value":560050.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":578065,"source":{"system":"sec-edgar","filing":"0000899243-22-021530","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021530/doc4.xml","form_type":"4"}},{"id":2242357,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-06","kind":"exercise","acquired":false,"shares":24382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the \"2016 Plan\") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement.  Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022."}],"balance_after":157958,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":24382},"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242356,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-03","kind":"exercise","acquired":false,"shares":25551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the \"2016 Plan\") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement.  Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022."}],"balance_after":182340,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":25551},"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242355,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-02","kind":"exercise","acquired":false,"shares":16689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 under the 2016 Stock Incentive Plan (the \"2016 Plan\") and was to vest in equal quarterly installments from January 1, 2019 through December 31, 2022, subject to the reporting person's continuous service on each such vesting date and thus ceased on March 31, 2022 when the reporting person's continuous service ceased upon termination of his consulting agreement.  Per terms of the award agreement under the 2016 Plan governing such option, the right to exercise this option will terminate June 30, 2022."}],"balance_after":207891,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":16689},"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242354,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-06","kind":"sale","acquired":false,"shares":24382,"price":8.104,"value":197591.728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.59, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242353,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-06","kind":"exercise","acquired":true,"shares":24382,"price":7.84,"value":191154.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":531012,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242352,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-03","kind":"sale","acquired":false,"shares":25551,"price":7.9471,"value":203056.3521,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242351,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-03","kind":"exercise","acquired":true,"shares":25551,"price":7.84,"value":200319.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":532181,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242350,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-02","kind":"sale","acquired":false,"shares":16689,"price":7.9191,"value":132161.8599,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.95, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2242349,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-06T23:00:13.000Z","date":"2022-06-02","kind":"exercise","acquired":true,"shares":16689,"price":7.84,"value":130841.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":523319,"source":{"system":"sec-edgar","filing":"0000899243-22-021250","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322021250/doc4.xml","form_type":"4"}},{"id":2299415,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-11T21:00:13.000Z","date":"2022-04-07","kind":"exercise","acquired":false,"shares":5631,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022."}],"balance_after":224580,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":5631},"source":{"system":"sec-edgar","filing":"0000899243-22-014438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322014438/doc4.xml","form_type":"4"}},{"id":2299414,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-11T21:00:13.000Z","date":"2022-04-07","kind":"sale","acquired":false,"shares":5631,"price":24.015,"value":135228.465,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.09, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-014438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322014438/doc4.xml","form_type":"4"}},{"id":2299413,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-11T21:00:13.000Z","date":"2022-04-07","kind":"exercise","acquired":true,"shares":5631,"price":7.84,"value":44147.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":512261,"source":{"system":"sec-edgar","filing":"0000899243-22-014438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322014438/doc4.xml","form_type":"4"}},{"id":2304368,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-05","kind":"exercise","acquired":false,"shares":52552,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022."}],"balance_after":230211,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":52552},"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304367,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-04","kind":"exercise","acquired":false,"shares":7235,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022."}],"balance_after":282763,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":7235},"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304366,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-01","kind":"exercise","acquired":false,"shares":34464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 22, 2019 and is scheduled to vest in equal quarterly installments from January 1, 2019 through December 31, 2022."}],"balance_after":289998,"derivative":{"exercise_price":7.84,"expiration_date":"2029-01-21","underlying":"Common Stock","underlying_shares":34464},"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304365,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-05","kind":"sale","acquired":false,"shares":52552,"price":24.2574,"value":1274774.8848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.75, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304364,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-05","kind":"exercise","acquired":true,"shares":52552,"price":7.84,"value":412007.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":559182,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304363,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":7235,"price":24.0151,"value":173749.2485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.05, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304362,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-04","kind":"exercise","acquired":true,"shares":7235,"price":7.84,"value":56722.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":513865,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304361,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-01","kind":"sale","acquired":false,"shares":34464,"price":24.0297,"value":828159.5808,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.17, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2304360,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-05T23:00:17.000Z","date":"2022-04-01","kind":"exercise","acquired":true,"shares":34464,"price":7.84,"value":270197.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2021."}],"balance_after":541094,"source":{"system":"sec-edgar","filing":"0000899243-22-013881","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924322013881/doc4.xml","form_type":"4"}},{"id":2782366,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-17T20:30:18.000Z","date":"2021-03-16","kind":"sale","acquired":false,"shares":789,"price":12.4279,"value":9805.6131,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.01 to $12.85, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":506630,"source":{"system":"sec-edgar","filing":"0000899243-21-012179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321012179/doc4.xml","form_type":"4"}},{"id":2782365,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-03-17T20:30:18.000Z","date":"2021-03-15","kind":"sale","acquired":false,"shares":9211,"price":12.1347,"value":111772.7217,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.51, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":507419,"source":{"system":"sec-edgar","filing":"0000899243-21-012179","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321012179/doc4.xml","form_type":"4"}},{"id":2850103,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-18T21:30:21.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":1673,"price":14.5649,"value":24367.0777,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $14.88, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":516630,"source":{"system":"sec-edgar","filing":"0000899243-21-007119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321007119/doc4.xml","form_type":"4"}},{"id":2850102,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-02-18T21:30:21.000Z","date":"2021-02-16","kind":"sale","acquired":false,"shares":6542,"price":14.1899,"value":92830.3258,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.48 to $14.47, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":518303,"source":{"system":"sec-edgar","filing":"0000899243-21-007119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321007119/doc4.xml","form_type":"4"}},{"id":2879189,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-04T21:35:18.000Z","date":"2021-02-02","kind":"grant","acquired":true,"shares":269390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 2, 2021 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2021, subject to continued service."}],"balance_after":269390,"derivative":{"exercise_price":11.33,"expiration_date":"2031-02-01","underlying":"Common Stock","underlying_shares":269390},"source":{"system":"sec-edgar","filing":"0000899243-21-004949","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321004949/doc4.xml","form_type":"4"}},{"id":2899262,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2021-01-22T21:30:10.000Z","date":"2021-01-20","kind":"sale","acquired":false,"shares":10000,"price":12.0826,"value":120826.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 1, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.365, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":524845,"source":{"system":"sec-edgar","filing":"0000899243-21-002928","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924321002928/doc4.xml","form_type":"4"}},{"id":3085595,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-07-09T20:15:54.000Z","date":"2020-07-08","kind":"sale","acquired":false,"shares":2500,"price":20,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":534845,"source":{"system":"sec-edgar","filing":"0000899243-20-018815","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320018815/doc4.xml","form_type":"4"}},{"id":3098463,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-26T20:15:21.000Z","date":"2020-06-25","kind":"sale","acquired":false,"shares":2500,"price":20.7968,"value":51992.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.32 to $21.26, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":537345,"source":{"system":"sec-edgar","filing":"0000899243-20-017758","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320017758/doc4.xml","form_type":"4"}},{"id":3114789,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-10T20:15:33.000Z","date":"2020-06-09","kind":"sale","acquired":false,"shares":156,"price":20,"value":3120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":539845,"source":{"system":"sec-edgar","filing":"0000899243-20-015959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015959/doc4.xml","form_type":"4"}},{"id":3116308,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-09T20:16:01.000Z","date":"2020-06-05","kind":"sale","acquired":false,"shares":3433,"price":20.1722,"value":69251.1626,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.31, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":540001,"source":{"system":"sec-edgar","filing":"0000899243-20-015784","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015784/doc4.xml","form_type":"4"}},{"id":3120363,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-05T20:26:55.000Z","date":"2020-06-04","kind":"sale","acquired":false,"shares":1300,"price":20.0446,"value":26057.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.01 to $20.10, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":543434,"source":{"system":"sec-edgar","filing":"0000899243-20-015437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015437/doc4.xml","form_type":"4"}},{"id":3120362,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-05T20:26:55.000Z","date":"2020-06-03","kind":"sale","acquired":false,"shares":1500,"price":20.1283,"value":30192.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.41, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":544734,"source":{"system":"sec-edgar","filing":"0000899243-20-015437","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015437/doc4.xml","form_type":"4"}},{"id":3124056,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-03T20:17:17.000Z","date":"2020-06-02","kind":"sale","acquired":false,"shares":2797,"price":20,"value":55940.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":546234,"source":{"system":"sec-edgar","filing":"0000899243-20-015063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015063/doc4.xml","form_type":"4"}},{"id":3124055,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-03T20:17:17.000Z","date":"2020-06-01","kind":"sale","acquired":false,"shares":5,"price":20,"value":100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":549031,"source":{"system":"sec-edgar","filing":"0000899243-20-015063","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320015063/doc4.xml","form_type":"4"}},{"id":3129063,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-01T20:15:47.000Z","date":"2020-05-29","kind":"sale","acquired":false,"shares":1390,"price":20.0797,"value":27910.783,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.22, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":549036,"source":{"system":"sec-edgar","filing":"0000899243-20-014721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320014721/doc4.xml","form_type":"4"}},{"id":3129062,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-06-01T20:15:47.000Z","date":"2020-05-28","kind":"sale","acquired":false,"shares":1919,"price":20.0058,"value":38391.1302,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.08, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":550426,"source":{"system":"sec-edgar","filing":"0000899243-20-014721","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320014721/doc4.xml","form_type":"4"}},{"id":3132166,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-05-28T20:15:57.000Z","date":"2020-05-26","kind":"sale","acquired":false,"shares":2500,"price":20,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":552345,"source":{"system":"sec-edgar","filing":"0000899243-20-014415","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320014415/doc4.xml","form_type":"4"}},{"id":3259522,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2020-02-20T21:24:02.000Z","date":"2020-02-19","kind":"sale","acquired":false,"shares":2500,"price":20,"value":50000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2019."}],"balance_after":554845,"source":{"system":"sec-edgar","filing":"0000899243-20-005300","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320005300/doc4.xml","form_type":"4"}},{"id":3301335,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President & CEO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-27T21:26:53.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 23, 2020 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2020, subject to continued service."}],"balance_after":200000,"derivative":{"exercise_price":16.87,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000899243-20-002035","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000089924320002035/doc4.xml","form_type":"4"}},{"id":3459194,"issuer":{"id":5969,"kind":"organization","name":"Fulcrum Therapeutics, Inc."},"owners":[{"id":32842,"kind":"person","name":"Gould Robert J","position":1,"cik":"0001577034","reported_name":"Gould Robert J","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2019-07-18T21:27:06.000Z","date":"2019-07-18","kind":"grant","acquired":true,"shares":107142,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest in equal quarterly installments from July 1, 2019 through June 30, 2023."}],"balance_after":107142,"derivative":{"exercise_price":16,"expiration_date":"2029-07-17","underlying":"Common Stock","underlying_shares":107142},"source":{"system":"sec-edgar","filing":"0001104659-19-040968","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1577034/000110465919040968/a4.xml","form_type":"4"}}]}